Case studies
Our case studies showcase our work within all phases of drug development. Each case clearly states the challenges and customer needs, and the services and solutions we provided.

Crovalimab dose justification based on Phase 3 data in paroxysomal nocturnal hemoglobinurea patients

Assessment of the probability of a drug asset to exceed the target efficacy value in major depression disorder trials using literature data of ketamine and esketamine

Model-informed microarray patches design for anti-retroviral drugs to treat children with HIV

Optimizing CAR-T cell exposure
In absence of clear dose-exposure relationships, there is a need to find other means to optimize CAR-T cell exposure.